Resistance matters in EARNEST

Affiliations

¹ Department of Medicine, University of Cape Town Health Sciences Faculty, Cape Town 7925, South Africa. Electronic address: gary.maartens@uct.ac.za.
² Department of Medicine, University of Cape Town Health Sciences Faculty, Cape Town 7925, South Africa.

Free article

Comment

Gary Maartens et al. Lancet HIV. 2017 Aug.

Free article

. 2017 Aug;4(8):e323-e324.

doi: 10.1016/S2352-3018(17)30087-5. Epub 2017 May 8.

¹ Department of Medicine, University of Cape Town Health Sciences Faculty, Cape Town 7925, South Africa. Electronic address: gary.maartens@uct.ac.za.
² Department of Medicine, University of Cape Town Health Sciences Faculty, Cape Town 7925, South Africa.

No abstract available

Comment on

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Paton NI, et al. Lancet HIV. 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub 2017 May 8. Lancet HIV. 2017. PMID: 28495562 Free PMC article.